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Summary ZD1694 ('Tomudex'), a novel, direct and specific thymidylate synthase (TS) inhibitor, was
developed in a collaborative research programme between Zeneca Pharmaceuticals and the Institute of Cancer
Research (UK) and entered clinical trials in 1991; phase II studies began in 1992, using 3.0 mg m2 every 3
weeks as a short 15 min infusion. Forty-six patients entered a phase II study of ZD1694 in advanced breast
cancer. A total of 74% of patients had received prior systemic therapy (either as adjuvant cytotoxic or
hormonal therapy or hormone therapy for advanced disease); 39% had received prior adjuvant cytotoxic
chemotherapy. All patients had measurable disease and 50% had liver metastases. In all 43 patients were
evaluable for response. Of these patients 26% achieved complete (CR) or partial response (PR) (95% Cl 14-
42%). A response rate of 44% was seen in liver metastases. Two patients achieved CR of 265 and 301 days'
duration respectively, one in locoregional disease, and one in liver metastases. The most common grade 3/4
adverse events were nausea and vomiting (11%), diarrhoea (11%) and leucopenia (20%). Grade 3/4, self-
limited and reversible increases in transaminases were seen in 22% of patients. ZD1694 has useful single agent
activity in patients with hormone-refractory advanced breast cancer, comparable with that reported for other
anti-metabolites, with acceptable tolerability.
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ZD1694 ('Tomudex'*) is a novel quinazoline anti-folate,
developed in a collaborative research programme. The goal
of the programme was to identify direct and specific
inhibitors of thymidylate synthase (TS), thus avoiding the
non-specific effects (upon protein synthesis and RNA) of
agents such as methotrexate (MTX) and 5-fluorouracil (5FU)
which are believed to play a role in the toxicity profiles
(leucopenia, mucositis) of these drugs. ZD1694 undergoes
extensive intracellular polyglutamation (Jackman et al.,
1993). This effectively causes it to be retained within the
cell and therefore allows a convenient intermittent (3 weekly)
schedule. Preclinical data and phase I data indicated activity
in breast cancer, and a phase I study defined a recommended
dose of 3.0 mg m-2, i.v. 3 weekly, with dose-limiting
toxicities of leucopenia, diarrhoea, tiredness/asthenia and
self-limited asymptomatic rises in transaminase levels (Clarke
et al., 1994). We report here on the results of a phase II
evaluation of ZD1694 in patients with advanced, hormone-
refractory breast cancer.
Patients and methods
Patient selection and trial therapy
Patients were accrued to the study between October 1992 and
November 1993. All patients had histologically confirmed
locally advanced or metastatic breast cancer, and may have
received endocrine therapy, either as adjuvant therapy or as
treatment for advanced disease. Patients may not have
received cytotoxic chemotherapy, unless as adjuvant therapy
at least 6 months prior to study entry. All patients had at
least one measurable lesion according to WHO criteria
(World Health Organization, 1979), a performance status
(PS) of 2 or less, normal haematology and acceptable
biochemistry parameters (except in the case of proven
hepatic metastases, when liver transaminases up to 5 times
the upper normal range were permissible), and may not have
had more than 30% of their bone marrow irradiated. All
patients gave informed consent, approval was obtained from
a recognised Ethics Committee at each trial centre, and the
study was performed according to the Declaration of
Helsinki (The Declaration of Helsinki, 1989). Patients
received ZD1694 at a dose of 3.0 mg m-2 as a short
15 min infusion every 3 weeks; if required, subsequent doses
could be delayed for a maximum of 21 days until toxicity had
resolved, and dose modification was performed according to
the worst WHO grade of haematological toxicity (WBC,
granulocyte and platelet counts) and diarrhoea experienced
with the previous cycle. Patients with grade IV diarrhoea, or
those with grade III diarrhoea in combination with grade II
or greater haematological toxicity were to be withdrawn from
treatment. Patients with lesser grades of toxicity received
further courses of therapy at 75% or 50% of the previous
dose.
Response and adverse event assessment
WHO and UICC recommendations (World Health Organiza-
tion, 1979; Hayward et al., 1977) for measurable and
evaluable lesions, and for objective response were used. The
study was designed such that recruitment of 40 patients to the
study would provide 92% power to detect a response rate of
20%. A one-sample multiple testing procedure was used
during patient accrual to allow for early termination of the
trial if initial results were extreme (Fleming, 1982).
Pretreatment evaluations included full clinical examina-
tion, objective tumour assessment, haematology and bio-
chemistry. Haematology and toxicity assessment was
performed weekly, biochemistry 3 weekly and objective
response assessment 6 weekly during the conduct of the
study.
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Results
Forty-six patients were entered into the study. Patient
characteristics are presented in Table I. The mean age of
the patients was 58 years (31-77 years), the majority had a
good PS and the most frequent sites of metastatic disease
were liver (50%) and bone (41%). Eighteen patients (39%)
had received prior adjuvant chemotherapy, half of these with
an anthracycline-based regimen. No patient had received
cytotoxic chemotherapy for advanced disease. A total of 19
patients (including three who had received adjuvant
chemotherapy) had received systemic endocrine therapy
within the 3 months before entry to the study.
Objective response
A total of 43 patients were evaluable for objective response
(one patient had no measurable disease at entry, and two had
only baseline evaluations performed). Table II summarises
the objective assessment data from all 43 patients, while
Table III summarises details of response in sites of
measurable disease. Both patients who achieved a complete
response (CR) did so after two cycles of treatment, and had a
duration of 265 and 301 days respectively; one patient had
locoregional disease while the other had liver metastases. Of
note, the patient with locoregional disease who achieved a
CR, achieved a second CR after relapse and rechallenge with
ZD1694, and at the time of writing this report, remains in
CR. The median duration of partial response (PR) was 209
days (range 55-575 days, mean 258 days). Of interest is the
high percentage of response in liver lesions (44%). The eight
responding patients with liver lesions had lesion sizes
(product of dimensions) at baseline ranging from 3 cm2 to
over 100 cm2, the majority having sizes between 7 and
15 cm2. Three of these eight patients had deranged LFTs at
baseline. Overall, the complete and partial objective response
rate in evaluable patients was 26% (95% confidence interval
14-42%). An additional 17 patients (40%) had either minor
responses or stable disease. On an intention to treat analysis
of objective response including all patients, the objective
response rate was 23%.
Adverse events
A total of 187 cycles of ZD1694 were administered, with a
mean of four, and a range of one to ten cycles. Overall 85%
of the patients were able to receive their scheduled dose of
ZD1694 without significant dose reduction or delay. All 46
patients entered into the study were evaluated for adverse
events. Table IV presents reported adverse events, irrespective
of relationship to the study treatment. The most frequently
reported grade 3 or 4 adverse events were self-limited
increases in liver transaminases (22%), which were generally
asymptomatic and reversible. Leucopenia (grade 3 or 4) was
reported in 20% ofpatients, and was usually transient. Grade
3 and 4 vomiting and diarrhoea was reported in 11% of
patients; of note, prophylactic anti-emetics were not
recommended in this study. Other adverse events were less
common and are presented in Table IV. Increases in urea and
creatinine levels were grade 1 and appeared to be related to
volume depletion after diarrhoea or vomiting. Cutaneous
effects and alopecia were unusual.
Three patients died from possible drug-related events
during the study; two of these patients had experienced
substantial gastrointestinal and haematological toxicity with
the previous cycle and had not received appropriate dose
modification. One of these two patients died of pneumonia,
for which she was not actively treated. The second died from
Table I Patient characteristics
Number Percentage
Ethnic background
Caucasian 45 98
Performance status
0 16 35
1 26 56
2 4 9
Sites of disease
Two or more viscera involved 7 15
Three or more sites of metastases 10 22
Bone 19 41
Nodal 13 28
Skin/soft tissue 11 24
Liver 23 50
Lung 12 26
Othera 9 20
Prior therapy
Surgery 39 85
Radiation treatment 30 65
Adjuvant cytotoxic therapy 18 39
Anthracycline-based 9 20
Other 9 20
Endocrine therapy within 90 days of
entry 19 41
aSix involved pleura.
Table II Objective disease assessment
Number Percentage
Complete response 2 5
Partial response 9 21
Minor responsea 7 16
Stable disease 10 23
No response 15 35
Total evaluable 43 100
aA 40-49% decrease in sum ofarea oflesions.
Table HI Objective response rate according to
lesion and prior therapy
sites of measurable
Pecentage
Number response
Site
Liver 18 44
Locoregional 8 25
Skin and soft tissue 6 33
Abdominal mass 3 33
Lung 3 33
Lymph node 5 20
Bone 3 0
Prior therapy
Prior adjuvant 18 17
chemotherapy
Prior anthracycline 9 11
chemotherapy
Table IV Adverse events, irrespective ofcausality, graded according
to WHO recommendations
Grade I Grade 2 Grade 3 Grade 4
Anaemia 4% 7% 4% 4%
Leucopenia 2% 0% 11% 9%
Thrombocytopenia 2% 2% 4% 2%
Diarrhoea 20% 7% 7% 4%
Mucositis 11% 2% 0% 0%
Rash 11% 0% 0% 0%
Nausea and vomiting 76% 35% 9% 2%
Alopecia 7% 0% 2% 0%
Infection 4% 9% 2% 0%
Astheniaa 9% 22% 2% NA
AST/ALT increases 2% 4% 17% 4%
Urea/creatine 4% 0% 0% 0%
aMild, moderate or severe.ZD1694 in advanced breast cancer
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gastrointestinal haemorrhage associated with disseminated
intravascular coagulation. The third patient died with a
combination of gastrointestinal and haematological toxicity.
Discussion
ZD1694 is a quinazoline anti-folate developed during a
rational drug design and research collaboration between the
Institute of Cancer Research and Zeneca Pharmaceuticals
(Jackman et al., 1993). It is a potent, direct and specific
inhibitor of TS and was predicted to offer toxicity benefits
owing to the lack of non-specific, non-TS effects on RNA
and purine metabolism that are seen with drugs such as MTX
and 5FU. ZD1694 undergoes intracellular polyglutamation
with the formation of potent polyglutamates allowing
prolonged drug action (Jackman et al., 1993). A convenient
single-dose intermittent (3 weekly) schedule is therefore
appropriate.
This schedule was confirmed in a phase I study with the
drug, which defined a maximum tolerated dose (MTD) of
3.5 mg m-2. A dose of 3.0 mg m-2 was recommended for
phase II studies (Clarke et al., 1994). Dose-limiting and dose-
related toxicities in phase I studies were haematological
(reversible leucopenia), gastrointestinal (diarrhoea), tiredness
or asthenia, and reversible self-limited rises in liver
transaminases.
Based on the dosing and scheduling recommendations
from the phase I study, a phase II programme was initiated
in eight tumour types. These included studies in platinum
refractory ovarian cancer, previously treated small-cell lung
cancer and gastric cancer, previously untreated colorectal
cancer, pancreatic, hepatocellular and non-small-cell lung
cancer, and as first-line chemotherapy for advanced breast
cancer. While objective responses have been reported in a
range of tumour types (Cunningham et al., 1994), the most
interesting activity, apart from that seen in breast cancer, has
been seen in colorectal cancer (Adenis et al., 1994), with final
response rates in a large (177 patients) phase II study being
26% (95% CI 19-33%). The drug is now completing
international phase III studies in this indication.
This report describes the phase II study conducted in 46
patients, many of whom had hormone-refractory advanced
breast cancer or had received adjuvant cytotoxic chemother-
apy. The overall objective response rate in this study was
26% (95% CI 14-42%). Two patients achieved sustained
CRs, (265-301 days), and one of these patients had a second
sustained CR when rechallenged after relapse. Of interest,
there was a high response rate (44%) in patients with
measurable liver lesions.
ZD1694 was in general well tolerated, with 85% of the
patients able to receive their scheduled dose of ZD1694
without significant delay or modification. The most
frequently reported adverse events were self-limited increases
in liver transaminases, leucopenia and diarrhoea. Alopecia
was remarkable for its low incidence.
The response rate in this study compares favourably with
reported response rates in the older literature using less
stringent response criteria (Hoogstraten and Fabian, 1979)
for other anti-metabolites such as MTX and 5FU. Studies
with other agents such as paclitaxel and docetaxel have
reported response rates of between 30% and 67% in small
phase II studies but may be associated with significant
toxicity, including hypersensitivity, bone marrow suppression,
fluid retention, pruritis and myalgia (Gianni et al., 1994;
Chevallier et al., 1995).
ZD1694 is the product of a rational drug design
programme and has useful activity in advanced hormone-
refractory breast cancer. The acceptable safety profile
suggests that further studies with the drug in combination
chemotherapy regimens are appropriate, and in particular as
a substitute for methotrexate and or 5-fluorouracil.
Acknowledgement
Supported by a research grant from Zeneca Pharmaceuticals UK.
References
ADENIS A, CUNNINGHAM D, VAN CUTSEM E, ZALCBERG J,
FRANCOIS E, SCHORNAGEL JH, GREEN M, STARKHAMMER
H, PEREZ-MANGA G AND SEYMOUR L (STUDY GROUP). (1994).
ZD1694 (ZD1694), a new active agent in the treatment of
advanced colorectal cancer. Ann. Oncol., 5, (suppl. 8), 189.
CHEVALIER B, FUMOLEAU P, KERBRAT P, DIERAS V, ROCHE H,
KRAKOWSKI I, AZLI N, BAYSSAS M, LENTZ MA AND VAN
GLABBEKE M. (1995). Docetaxel is a major cytotoxic drug for the
treatment ofadvanced breast cancer: a phase II trial ofthe clinical
screening cooperative group ofthe European Organisation for the
Research and Treatment ofCancer. J. Clin. Oncol., 13, 314- 322.
CLARKE SJ, WARD J, DE BOER M, PLANTING A, VERWEIJ J,
SUTCLIFFE F, AZAB M AND JUDSON IR. (1994). Phase I study of
the new thymidylate synthase inhibitor ZD1694 (ZD1694) in
patients with advanced malignancy. Ann. Oncol., 5, (suppl. 5),
132.
CUNNINGHAM D, ZALCBERG J, SMITH IE, GORE M, PAZDUR R,
BURRIS H, AZAB M AND KENNEALEY G (STUDY GROUP).
(1994). ZD1694: a novel thymidylate synthase (TS) inhibitor with
clinical antitumour activity in a range of solid tumours. Ann.
Oncol., 5, (suppl. 8), 179.
FLEMING TR. (1982). One sample multiple testing for phase II
clinical trials. Biometrics, 38, 143 - 151.
GIANNI L, CAPRI G, MUNZONE E AND STRANEO M. (1994).
Paclitaxel (taxol) efficacy in patients with advanced breast cancer
resistant to anthracyclines. Semin. Oncol., 21, 29-33.
HAYWARD JL, CARBONE PP, HEUSON JC, KUMAOKA S, SEGAL-
OFF A AND RUBENS RD. (1977). Assessment of response to
therapy in advanced breast cancer. Eur J Cancer, 13, 89-94.
HOOGSTRATEN B AND FABIAN C. (1979). A reappraisal of single
drugs in advanced breast cancer. Cancer Clin. Trials, 2, 101 - 109.
JACKMAN AL, GIBSON W, BROWN M, KIMBELL R AND BOYLE FT.
(1993). The role of the reduced folate carrier and metabolism to
intracellular polyglutamates for the activity of ICI Dl 694. Adv.
Exp. Med. Biol., 339, 265-276.
THE DECLARATION OF HELSINKI. (1989). Recommendations
guiding physicians in biomedical research involving human
subjects. 41st World Medical Assembly, Hong Kong.
WORLD HEALTH ORGANIZATION. (1979). WHO Handbook for
Reporting Results ofCancer Treatment, World Health Organiza-
tion: Geneva.